59815-19-9

Basic information

• Product Name: 3-(aminosulfonyl)-4-bromobenzoic acid
• Synonyms: 3-(aminosulfonyl)-4-bromobenzoic acid
• CAS NO: 59815-19-9
• Molecular Formula: C₇H₆BrNO₄S
• Molecular Weight: 280.1
• Mol File: 59815-19-9.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(aminosulfonyl)-4-bromobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(aminosulfonyl)-4-bromobenzoic acid(59815-19-9)
• EPA Substance Registry System: 3-(aminosulfonyl)-4-bromobenzoic acid(59815-19-9)

Safety Data

• Hazardous Substances Data: 59815-19-9(Hazardous Substances Data)

Usage

General Description

3-(aminosulfonyl)-4-bromobenzoic acid, also known as Bromamine acid, is a chemical compound with the molecular formula C7H6BrNO4S. It is a member of the benzoic acid family and is commonly used in the synthesis of pharmaceuticals and dyes. The compound contains a bromine atom, a sulfonamide group, and a carboxylic acid group, making it useful in a variety of chemical reactions. Bromamine acid is often employed as an intermediate in the production of various organic compounds due to its versatile reactivity and functional groups. It is also used as a reagent in analytical chemistry for the detection of amines and other organic compounds.

Upstream product

• 50803-23-1 4-bromo-3-(chlorosulfonyl)benzoic acid 
• 586-76-5 4-Bromobenzoic acid 

Downstream Products

• 35588-54-6 4-bromo-3-sulfamoylbenzoyl chloride 
• 59815-21-3 4'-bromo-3'-sulfamoyl-2-chloroacetophenone 
• 74451-73-3 2-bromo-5-carbomethoxybenzenesulfonamide 
• 1310552-64-7 methyl-4-bromo-3-tetrahydro-1H-2-pyrrolydensulfamoylbenzoate 
• 1310552-65-8 methyl-3-(2-azepanylidensulfamoyl)-4-bromobenzoate 

Relevant articles and documents

Design, synthesis and biological evaluation of 5?substituted sulfonylureas as novel antifungal agents targeting acetohydroxyacid synthase

Acetohydroxyacid synthase (AHAS; EC2.2.1.6) exists solely in plants and microbes, and the biosynthesis of branched chain amino acids (valine, leucine and isoleucine) gets obstructed when sulfonylureas bind to AHAS catalytic subunit active site, which leads to the inability to synthesize these proteins and eventually causes the death of plants and microbes. Thus, the AHAS is also a promising antifungal target. Nowadays, there is an urgent need to discover new potential targets and chemical structures to prevent the growing morbidity and mortality of fungal infections and the emergence of severe antifungal drug resistance. In this work, 36 target compounds were designed and synthesized and several 5-substituted sulfonylureas possess much better antifungal activities than those of Fluconazole (FCZ) and amphotericin B (AMB). The most potent of these were L10, L23 and L31 with inhibition constants (Ki) determined in the range of 5.6～9.6 nM for C. albicans AHAS and MICs(The MIC was determined as the drug concentration that inhibits fungal growth by >90% relative to the corresponding drug-free growth control) a proposed double-pocket binding mode was simulated via molecular docking. The energy gap between the HOMOs and LUMOs of selected compounds showed that the 5-substituted groups of sulfonylureas have key impact on the antimicrobial bioactivity.

CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS

The present invention relates to compounds of formula (I) or pharmaceutically acceptable derivatives thereof, useful in the treatment or prophylaxis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).